Insulet Co. (NASDAQ:PODD) Shares Sold by Xponance Inc.

Xponance Inc. lessened its stake in Insulet Co. (NASDAQ:PODD) by 8.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 15,466 shares of the medical instruments supplier’s stock after selling 1,346 shares during the period. Xponance Inc.’s holdings in Insulet were worth $3,356,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in PODD. Parkside Financial Bank & Trust grew its holdings in Insulet by 251.0% in the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 123 shares in the last quarter. Allworth Financial LP grew its holdings in shares of Insulet by 104.5% in the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 92 shares during the period. Wolff Wiese Magana LLC grew its holdings in shares of Insulet by 2,680.0% in the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 134 shares during the period. BluePath Capital Management LLC acquired a new stake in Insulet during the third quarter worth about $31,000. Finally, First Manhattan Co. acquired a new position in Insulet in the 4th quarter valued at about $35,000.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PODD. Barclays cut their price target on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a report on Monday, February 26th. Piper Sandler cut their target price on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research note on Friday, February 23rd. JPMorgan Chase & Co. upped their price target on Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. Finally, Stifel Nicolaus raised their price objective on Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research report on Monday, February 5th. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $243.21.

Insider Transactions at Insulet

In related news, Director Shacey Petrovic sold 11,609 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total value of $1,891,338.28. Following the sale, the director now owns 2,567 shares of the company’s stock, valued at $418,215.64. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.80% of the company’s stock.

Insulet Stock Performance

Shares of PODD stock opened at $166.25 on Monday. The firm has a 50 day moving average of $173.97 and a two-hundred day moving average of $179.15. The stock has a market capitalization of $11.64 billion, a PE ratio of 57.13, a P/E/G ratio of 2.99 and a beta of 0.98. The company has a quick ratio of 2.62, a current ratio of 3.51 and a debt-to-equity ratio of 1.86. Insulet Co. has a 52 week low of $125.82 and a 52 week high of $335.91.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.73. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The firm had revenue of $509.80 million during the quarter, compared to analyst estimates of $461.26 million. During the same period last year, the business posted $0.55 earnings per share. Insulet’s revenue was up 37.9% compared to the same quarter last year. On average, research analysts predict that Insulet Co. will post 3.08 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.